Innovation-driven development
Technical platform
BIBP focuses on building a diversified technology platform, strengthening its traditional strengths; building an internationally leading technology platform for new inactivated vaccines; developing “pentavaccine”, “hexavaccine” and other polyvalent vaccines that are urgently needed in China, developing combined and multivalent vaccine technology system with independent intellectual property rights in China; building a technology platform for live attenuated vaccines, a manufacturing platform for highly pathogenic pathogens and a new technology platform for cancer treatment to solve the “bottleneck” dilemma of key fields in China; expanding the scope and depth of cooperation with domestic and foreign scientific research institutes; establishes special research and development laboratories, and expanding direction of the output of key achievements in scientific and technological innovation.
View More
COVID-19 vaccine
COVID-19 is the most widespread pandemic to hit humanity in a century. The Communist Party of China (CPC) Central Committee and The State Council have attached great importance to emergency efforts in vaccine research and development.Under the overall deployment of Sinopharm CNBG, BIBP shouldered the responsibility, spared no efforts to actively carry out scientific research and development, which developed the first approved inactivated COVID-19 vaccine in the world, and achieved mass production on a large scale of the vaccine to meet the requirements of national major public health security and to provide important support for the establishment of an immune barrier in China and even the world.
View More
Areas of concern
Be down-to-earth, pioneering and innovative, dare to be the first, dare to make breakthroughs, and focus on solving the country's most important, critical and urgent scientific and technological problems in the field of biomedicine from the long-term needs of the country.
◎ Provide safe and effective vaccines for national immunization program
◎ Provide crucial vaccines for the country to overcome the outburst of serious infectious diseases and to guard public health security
◎ Provide key products and technologies for people’s life and health, also for China’s major public health needs
◎ Strategic leading technologies in the field of international biomedicine
Scientific research team
BIBP has an international elite team composed of several senior experts, professional technicians, etc. More than 85% of the team members have postgraduate degrees and 35% have doctoral degrees. The R&D team has prominently spearheaded serveral tasks of developing preventive products and assuring emergency supplies for serious infectious diseases.
The team and its members have won honorary titles such as “Advanced Collective of Central State-owned Enterprises”, “Advanced Collective of Beijing Municipality in the Fight Against COVID-19”, “Advanced Collective of the Sixth National Professional and Technical Talents”, “National Bearer of Red Flag March 8 in the Fight Against COVID-19”, “Outstanding Young Engineer of Beijing Municipality”, “New Star in Science and Technology of Beijing Municipality”, etc.
Contact us
